Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

J.K. Doorduijn*, J.M. Zijlstra, P.J. Lugtenburg, M.J. Kersten, L.H. Bohmer, M.C. Minnema, M.A. MacKenzie, R.V. Kooij, E. de Jongh, T.J.F. Snijders, O. de Weerdt, M. van Gelder, M. Hoogendoorn, R.B.L. Leys, R.E. Kibbelaar, D. de Jong, D.A. Chitu, M.B. Van't Veer, H.C. Kluin-Nelemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Web of Science)
Original languageEnglish
Pages (from-to)385-393
Number of pages9
JournalBritish Journal of Haematology
Volume190
Issue number3
DOIs
Publication statusPublished - 1 Aug 2020

Keywords

  • beam
  • bortezomib
  • cytarabine
  • high-dose cytarabine
  • immunochemotherapy
  • maintenance therapy
  • mantle cell lymphoma
  • mcl younger
  • multicenter
  • nordic mcl2
  • phase ii trial
  • randomised
  • rescue
  • rituximab
  • survival
  • SURVIVAL
  • IMMUNOCHEMOTHERAPY
  • RITUXIMAB
  • NORDIC MCL2
  • MCL YOUNGER
  • MULTICENTER
  • HIGH-DOSE CYTARABINE
  • BEAM
  • RESCUE
  • Mantle cell lymphoma
  • phase II trial

Cite this